Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

361 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Abnormal expression of the genes involved in cytokine networks and mitochondrial function in systemic juvenile idiopathic arthritis identified by DNA microarray analysis.
Ishikawa S, Mima T, Aoki C, Yoshio-Hoshino N, Adachi Y, Imagawa T, Mori M, Tomiita M, Iwata N, Murata T, Miyoshi M, Takei S, Aihara Y, Yokota S, Matsubara K, Nishimoto N. Ishikawa S, et al. Among authors: nishimoto n. Ann Rheum Dis. 2009 Feb;68(2):264-72. doi: 10.1136/ard.2007.079533. Epub 2008 Apr 3. Ann Rheum Dis. 2009. PMID: 18388159
Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Yokota S, et al. Among authors: nishimoto n. J Rheumatol. 2014 Apr;41(4):759-67. doi: 10.3899/jrheum.130690. Epub 2014 Mar 15. J Rheumatol. 2014. PMID: 24634205 Clinical Trial.
Interleukin 11 and paired immunoglobulin-like type 2 receptor alpha expression correlates with the number of joints with active arthritis in systemic juvenile idiopathic arthritis.
Mima T, Ishikawa S, Aoki C, Yoshio-Hoshino N, Adachi Y, Imagawa T, Mori M, Tomiita M, Iwata N, Murata T, Miyoshi M, Takei S, Aihara Y, Yokota S, Matsubara K, Nishimoto N. Mima T, et al. Among authors: nishimoto n. Ann Rheum Dis. 2009 Feb;68(2):286-7. doi: 10.1136/ard.2008.091041. Ann Rheum Dis. 2009. PMID: 19139207 No abstract available.
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Yokota S, et al. Among authors: nishimoto n. Lancet. 2008 Mar 22;371(9617):998-1006. doi: 10.1016/S0140-6736(08)60454-7. Lancet. 2008. PMID: 18358927 Clinical Trial.
Gene therapy for multiple myeloma.
Adachi Y, Yoshio-Hoshino N, Nishimoto N. Adachi Y, et al. Among authors: nishimoto n. Curr Gene Ther. 2008 Aug;8(4):247-55. doi: 10.2174/156652308785160683. Curr Gene Ther. 2008. PMID: 18691020 Review.
Clinical value of blocking IL-6 receptor.
Mima T, Nishimoto N. Mima T, et al. Among authors: nishimoto n. Curr Opin Rheumatol. 2009 May;21(3):224-30. doi: 10.1097/BOR.0b013e3283295fec. Curr Opin Rheumatol. 2009. PMID: 19365268 Review.
Tocilizumab for the treatment of rheumatoid arthritis.
Mima T, Nishimoto N. Mima T, et al. Among authors: nishimoto n. Expert Rev Clin Immunol. 2008 Mar;4(2):165-72. doi: 10.1586/1744666X.4.2.165. Expert Rev Clin Immunol. 2008. PMID: 20477048
361 results